Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas E Witzig

Showing results (141-150 of 387) with videos related to

Pageof 39
Sort By:
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab eraGrzegorz S Nowakowski, Matthew J Maurer, Thomas M Habermann, et al.
American Journal of Hematology|June 15, 2017
Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU)Thomas E Witzig, Patrick B Johnston, Betsy R LaPlant, et al.
American Journal of Hematology|October 19, 2011
Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphomaCarrie A Thompson, Matthew J Maurer, James R Cerhan, et al.
Cancer|May 13, 2008
Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment GroupDavid J Inwards, Paul A S Fishkin, David W Hillman, et al.
Pharmacotherapy|November 5, 2023
Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphomaMikhaila L Rice, Erin F Barreto, Andrew D Rule, et al.
Journal of Travel Medicine|March 8, 2013
A randomized, double blind, placebo-controlled trial of an oral synbiotic (AKSB) for prevention of travelers' diarrheaAbinash Virk, Jayawant Mandrekar, Elie F Berbari, et al.
International Journal of Cancer|December 26, 2006
Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instabilityFrank A Sinicrope, Rafaela L Rego, Megan M Garrity-Park, et al.
British Journal of Haematology|July 14, 2011
Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistanceMarek Mraz, Clive S Zent, Amy K Church, et al.
Journal of Pharmacy Practice|February 20, 2026
Pharmacist Perspectives on High-Dose Methotrexate Management and Acute Kidney Injury Risk Mitigation in Patients With Lymphoma: Results From a National SurveyElizabeth B King, Mikhaila L Rice, Huong L Truong, et al.
Blood|December 13, 2005
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification systemDavid Dingli, Grzegorz S Nowakowski, Angela Dispenzieri, et al.
Pageof 39

Showing results (141-150 of 387) with videos related to

Sort By:
Pageof 39
Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|December 17, 2009
Statin use and prognosis in patients with diffuse large B-cell lymphoma and follicular lymphoma in the rituximab eraGrzegorz S Nowakowski, Matthew J Maurer, Thomas M Habermann, et al.
American Journal of Hematology|June 15, 2017
Long-term follow-up of chemoimmunotherapy with rituximab, oxaliplatin, cytosine arabinoside, dexamethasone (ROAD) in patients with relapsed CD20+ B-cell non-Hodgkin lymphoma: Results of a study of the Mayo Clinic Cancer Center Research Consortium (MCCRC) MC0485 now known as academic and community cancer research united (ACCRU)Thomas E Witzig, Patrick B Johnston, Betsy R LaPlant, et al.
American Journal of Hematology|October 19, 2011
Elevated serum free light chains are associated with inferior event free and overall survival in Hodgkin lymphomaCarrie A Thompson, Matthew J Maurer, James R Cerhan, et al.
Cancer|May 13, 2008
Long-term results of the treatment of patients with mantle cell lymphoma with cladribine (2-CDA) alone (95-80-53) or 2-CDA and rituximab (N0189) in the North Central Cancer Treatment GroupDavid J Inwards, Paul A S Fishkin, David W Hillman, et al.
Pharmacotherapy|November 5, 2023
Development and validation of a model to predict acute kidney injury following high-dose methotrexate in patients with lymphomaMikhaila L Rice, Erin F Barreto, Andrew D Rule, et al.
Journal of Travel Medicine|March 8, 2013
A randomized, double blind, placebo-controlled trial of an oral synbiotic (AKSB) for prevention of travelers' diarrheaAbinash Virk, Jayawant Mandrekar, Elie F Berbari, et al.
International Journal of Cancer|December 26, 2006
Alterations in cell proliferation and apoptosis in colon cancers with microsatellite instabilityFrank A Sinicrope, Rafaela L Rego, Megan M Garrity-Park, et al.
British Journal of Haematology|July 14, 2011
Bone marrow stromal cells protect lymphoma B-cells from rituximab-induced apoptosis and targeting integrin α-4-β-1 (VLA-4) with natalizumab can overcome this resistanceMarek Mraz, Clive S Zent, Amy K Church, et al.
Journal of Pharmacy Practice|February 20, 2026
Pharmacist Perspectives on High-Dose Methotrexate Management and Acute Kidney Injury Risk Mitigation in Patients With Lymphoma: Results From a National SurveyElizabeth B King, Mikhaila L Rice, Huong L Truong, et al.
Blood|December 13, 2005
Flow cytometric detection of circulating myeloma cells before transplantation in patients with multiple myeloma: a simple risk stratification systemDavid Dingli, Grzegorz S Nowakowski, Angela Dispenzieri, et al.
Pageof 39